Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefitA recent review found no clear benefit for Parkinsons disease patients taking GLP-1 drugs compared to placebo

Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology Published May 10, 2026 Study authors: Mendonça Miguel F, Interaminense Arthur C, do R Barros Guilherme S T, Rabelo Luciana A, de Oliveira … PubMed ↗ DOI ↗ Editorial oversight: Dr. Ji-eun Park, MD · Brain, Mind & Pain

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway

Consider that GLP-1 agonists show no consistent motor benefit in Parkinson's disease and may increase gastrointestinal adverse events.

This is a meta-analysis of randomized controlled trials evaluating GLP-1 receptor agonists for Parkinson's disease. The scope included motor function improvements measured by the MDS-UPDRS Part III and other secondary outcomes.

The authors synthesized findings showing no statistically significant difference in motor and non-motor outcomes across MDS-UPDRS Parts I, II, III, and IV. For quality of life assessed by the PDQ-39, the mean difference was -0.75 (95% CI: [-1.34, -0.17], P = 0.01), favoring GLP-1 receptor agonists.

Safety data indicated GLP-1 receptor agonists were associated with a higher incidence of adverse events, especially gastrointestinal effects such as nausea, vomiting, and constipation. Serious adverse events and discontinuations were not reported.

The authors note that current evidence does not demonstrate consistent clinical benefit for motor or non-motor symptoms, nor support GLP-1 receptor agonists as disease-modifying therapy. Limitations were not detailed in the source.

Practice relevance is restrained; clinicians should not infer disease-modifying effects or recommend these agents for Parkinson's disease treatment based on this evidence.

This review looked at several studies comparing GLP-1 receptor agonists to a placebo for people with Parkinsons disease. The main goal was to see if these drugs helped with movement problems or other symptoms. Researchers measured how well patients moved in both on and off medication states at different times during the trials.

The results showed that patients taking GLP-1 drugs had a tiny improvement in quality of life scores. However, there was no real difference in how well patients moved or handled daily tasks. The drugs did not change the course of the disease or stop it from getting worse.

Safety was also checked during the review. Patients taking GLP-1 drugs reported more stomach problems like nausea and vomiting. Because these side effects were common, doctors must weigh the small benefits against the risks before suggesting these medicines for Parkinsons disease.

What this means for you:

GLP-1 drugs did not help movement or daily life in Parkinsons disease and caused more stomach problems than placebo.

Study Details

Study typeMeta analysis

EvidenceLevel 1

PublishedMay 2026

PMID42105060

View Original Abstract ↓

BACKGROUND: Parkinson's disease (PD) is a progressive neurodegenerative disorder with no proven disease-modifying therapies to date. Because changes in cerebral glucose metabolism and insulin resistance have been linked to PD pathophysiology, glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for diabetes, have been investigated as potential neuroprotective treatments. METHODS: This study systematically assessed the efficacy and safety of GLP-1RAs in PD through a systematic review and meta-analysis of randomized controlled trials identified in PubMed, Embase, and the Cochrane Library. The primary outcomes were motor function improvements measured by the MDS-UPDRS Part III in both on- and off-medication states at study endpoints and at intermediate timepoints of interest. Secondary outcomes included MDS-UPDRS Parts I, II, and IV, quality of life assessed by the PDQ-39, levodopa equivalent daily dose (LEDD), and the occurrence of adverse events. RESULTS: The meta-analysis found no statistically significant difference in favor of GLP-1RAs over placebo for motors and non-motors outcomes, except for PDQ-39 (MD: - 0.75; 95% CI: [- 1.34, - 0.17], P = 0.01). Regarding safety, GLP-1RAs were associated with a higher incidence of adverse events, especially gastrointestinal effects such as nausea, vomiting, and constipation. CONCLUSIONS: Overall, current evidence does not demonstrate consistent clinical benefit of using GLP-1RAs for treating motor or non-motor symptoms in PD nor support GLP-1RAs as disease-modifying therapy, underscoring the need for further research.

Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefitA recent review found no clear benefit for Parkinsons disease patients taking GLP-1 drugs compared to placebo

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Meta-analysis of GLP-1 agonists for Parkinson's disease motor symptoms shows limited benefitA recent review found no clear benefit for Parkinsons disease patients taking GLP-1 drugs compared to placebo

More on Parkinson's Disease

Study Details

Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke

Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window

Clinical research that matters. Delivered to your inbox.

Related in Neurology

From Other Specialties